Encoded Therapeutics Raises $275M Series F to Take Its Dravet Gene Therapy Through Pivotal Development
GV and an unnamed healthcare fund co-led Encoded Therapeutics' $275 million Series F, financing pivotal ETX101 studies, internal GMP scale-up, and a 2027 IND target for ETX301.